Carboplatin (NSC 241240)

Catalog No.S1215 Synonyms: JM-8, CBDCA

For research use only.

Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Carboplatin (NSC 241240) Chemical Structure

CAS No. 41575-94-4

Selleck's Carboplatin (NSC 241240) has been cited by 86 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[6]
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\DNk0zPeLCid88US=> MYe3NkBp NFq3VHpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NHH6VGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO|ExPSd-Mk[xN|cyODV:L3G+
Tca8113/CBP  MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HxO|IuOjYkgJpOwG0> NHnxR3E4OiCq M4P5colvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NFfM[no9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO|ExPSd-Mk[xN|cyODV:L3G+
Tca8113/PYM  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfYNk0zPeLCid88US=> MVi3NkBp NWm4W|BZcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NEHy[HU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO|ExPSd-Mk[xN|cyODV:L3G+
SKOV3 M4jTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PjdVYxKG2pL33s MmjNNU02KGR? MXjpcohq[mm2czDj[YxtKH[rYXLpcIl1gSC2aX3lJIRmeGWwZHXueIx6 NYX0cnBnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|cxPDNpPkK2NVM4ODR|PD;hQi=>
SKOV3 MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PFSFAuPCEQvHevcYw> MYGyOE81QC95MjDo NYPSZ4tpcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NUK3N{c,OjZzMkWyO|M9N2F-
SKOV3 M4Lpd2Fxd3C2b4Ppd{BCe3OjeR?= M1flXVIh|rypL33s MYS0PEBp M1HN[Ylv\HWlZYOgZZBweHSxc3nz MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NUK3N{c,OjZzMkWyO|M9N2F-
OSA NYDJZoVRS2yxbn;n[Y5q[yCDc4PhfS=> MWOyMlUwPSEQvF2= NETBU3Rz\XO3bITzJIlvKGyxd3XyJINwdG:weTDmc5Ju[XSrb36gZZMh[2:vcHHy[YQhfG9iZXn0bIVzKEKPSUGgd4lTVkFidILlZZRu\W62 NE\SRow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxNFYzOCd-Mk[xNVA3OjB:L3G+
A549 MoHMSpVkfGmxbjDBd5NigQ>? NGrZOWUxNzJ3L{WwJO69VQ>? NIfFSFYzPCCq MYrkc5dvemWpdXzheIV{KG2rUj2yNFUh\XiycnXzd4lwdsLi NWXSOlV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVc{OTdpPkK1PVE4OzF5PD;hQi=>
H1975 NWDZWYtHTnWldHnvckBCe3OjeR?= MkLLNE8zPS93MDFOwG0> MVGyOEBp NUP0V|dJ\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=> M33FflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUG3N|E4Lz5{NUmxO|MyPzxxYU6=
A549 MlS2SpVkfGmxbjDBd5NigQ>? M{XtWlAwOjVxNUCg{txO MnjCNlQhcA>? NX7EWFBbfXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975 NXyw[4ZbTnWldHnvckBCe3OjeR?= M4W3clAwOjVxNUCg{txO NV\BZ2ZIOjRiaB?= MXn1dJJm\3WuYYTld{BucVJvMkG4JIV5eHKnc4Ppc44> M3;r[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUG3N|E4Lz5{NUmxO|MyPzxxYU6=
A549 NVLKdGlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUiyOUDPxE1? NYHofXJ3OjRiaB?= NW\UZnA3cW6qaXLpeJMh[2WubDDndo94fGh? MlrtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N|E4RC:jPh?=
H1975 M2S5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\GNlUh|ryP NYPPc3A3OjRiaB?= MoW2bY5pcWKrdIOgZ4VtdCCpcn;3eIg> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
MDA-MB-231 NXj1O2Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvpZ4gxNTJ{MDFOwIcwdWx? NUXDOoFbPzJiaB?= NHvjdoRKSzVywrC9JFg3KM7:TR?= Mk\WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{e2PVEoRjJ3OEO3OlkyRC:jPh?=
T47D NIqxOHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr6WWRjOC1{MkCg{txoN22u NHnWOG84OiCq NVKyS5NHUUN3MNMgQUA1QC57IN88US=> NHe0dlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizO|Y6OSd-MkW4N|c3QTF:L3G+
LCTCC NX[2[lVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrRTWM2OD1|LklihKnDvU1? NEPQTIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3N|E3Pyd-MkW3O|MyPjd:L3G+
MCTCC NGewWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJwOPMAjeK2VQ>? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MegTCC MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e4V2lEPTB;ND6x5qCKyrWP MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MonoTCC NXTmbVVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\UTWM2OD13LkdihKnDvU1? NGjh[2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3N|E3Pyd-MkW3O|MyPjd:L3G+
MCF7 M1\R[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLDNlAh|ryP MX63NkBp NHK1V5NqdmS3Y3XzJINmdGxiZHXheIghd2ZiSGCx{tIu\GWybHX0[YQhVUOINzDj[Yxtew>? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4OUCyOUc,OjV5NkmwNlU9N2F-
A-549  MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTGdZozOC53IN88US=> MVyyOEBp NF3qdJRFVVORwrC= NXvzUFNUcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> NViw[25HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVU3QTBpPkK1O|U2PjlyPD;hQi=>
A-549  M3XXdmFxd3C2b4Ppd{BCe3OjeR?= MoX2NE42KM7:TR?= MmjpOFghcA>? MV;EUXNQyqB? M1vxVJNpd3e|IHXhdox6KGGyb4D0c5NqeyCoZXH0eZJmeyCrbnPseYRqdmdiYnzlZoJqdmdiYX7kJINpem:vYYTpckBkd26mZX7zZZRqd25? M2\4c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W1OlkxLz5{NUe1OVY6ODxxYU6=
A-549  MWXGeYN1cW:wIFHzd4F6 M4XEXVAvPSEQvF2= MkTxOFghcA>? NGPjS41FVVORwrC= Ml;Yd4hwf3NiYXLldpJidnRibXnjdo91fWK3bHWg[Il{enWydHnvci=> MkjKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUW2PVAoRjJ3N{W1OlkxRC:jPh?=
A-549  NEC3SmVHfWO2aX;uJGF{e2G7 NFzVXJUxNjVizszN Mmi4OFghcA>? NF70dJhFVVORwrC= MnfCbY5pcWKrdIOgc4Yh[2WubDDtbYdz[XSrb39CpC=> MoftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUW2PVAoRjJ3N{W1OlkxRC:jPh?=
RMG-1 NF3iU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJ6LkigxtEhOy54IH3nM2w> NX3Xb2YxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlY6OTNpPkK1O|I3QTF|PD;hQi=>
FN-RMG-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDnT2Y{UUN3ME20NE42KMLzIESuNkBu\y:OCjFOwG0> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{NkmxN{c,OjV5Mk[5NVM9N2F-
RMG-1-hFUT MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljqTWM2OD13OD6xJOKyKDJwNDDt[{9N MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{NkmxN{c,OjV5Mk[5NVM9N2F-
FN-RMG-1-hFUT NV\jUHlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\ZV5k3UUN3ME2xNVgvQCEEsTCxN{45KG2pL1y= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{NkmxN{c,OjV5Mk[5NVM9N2F-
CHP-134  M3XqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYixJO69VQ>? NEPsTplFVVORwrC= NHPnRY5qdmirYnn0d{B{cWewaX\pZ4FvfCClZXzsJIdzd3e2aDDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OES2N{c,OjV4NUi0OlM9N2F-
IMR-32 MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnaWXYyKM7:TR?= NUHuNZRKTE2VT9Mg MoTMbY5pcWKrdIOgd4lodmmoaXPhcpQh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBIW0t{OEOwN|cy MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OES2N{c,OjV4NUi0OlM9N2F-
CHP-134  MVHGeYN1cW:wIFHzd4F6 MUOxNEDPxE4EoB?= NFTwVFdFVVORwrC= NX71XYoxcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? MlzqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUi0OlMoRjJ3NkW4OFY{RC:jPh?=
IMR-32 M3HBWGZ2[3Srb36gRZN{[Xl? MV[xNEDPxE4EoB?= M2CwOmROW00EoB?= NITVfXBqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? NVi1WnJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVg1PjNpPkK1OlU5PDZ|PD;hQi=>
A549 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK4e2kxNjJvNECwNEDPxE1? NIrPNlc4OiCq MVTJR|UxRTF{NjFCtUA2NjBizszN NHvyNnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVI1Oyd-MkW2NlUzPDN:L3G+
A549/CDDP NYTY[2tTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUewMlIuPDByMDFOwG0> NW\aPYVZPzJiaB?= MmHVTWM2OD1{NEFCpOKyyqB2NT63JO69VQ>? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NUK0N{c,OjV4MkWyOFM9N2F-
H460  NEnheFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUW1Onk{OjRiaB?= NYPndlM{TE2VTx?= NUjtOFR4UUN3ME23Mlkh|ryP MmL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUm5PVUoRjJ3NUm5PVk2RC:jPh?=
H460  NGTVTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fXVVcvQSEQvF2= M1HKPFI1KGh? M{DXcGROW09? MX\zbI94eyCjIILh[Ilwe2Wwc3n0bZpqdmdiZX\m[YN1KHSxIGitdoF6ew>? MmP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUm5PVUoRjJ3NUm5PVk2RC:jPh?=
NRK-52E NHnFbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlqwO|LDqGkEoB?= MXLJR|UxRTFyMDFCtUAyOi57IN88US=> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4NU[wN{c,OjV3NkW2NFM9N2F-
RGE M3:5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYi3NuKhcMLi NWDFcFJ1UUN3ME2yNkDDuSB5LkSg{txO NUPBT2NCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlU3ODNpPkK1OVY2PjB|PD;hQi=>
NRK-52E MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVG3NuKhcMLi NWLNeZIyUUN6ME2xO|khyrFiOT61JO69VQ>? M2DHT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[1OlA{Lz5{NUW2OVYxOzxxYU6=
RGE NImwXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XGU|czyqCqwrC= MX\JR|gxRTZ|INMxJFcvPCEQvF2= M4\ZVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[1OlA{Lz5{NUW2OVYxOzxxYU6=
SK-OV-3 M{jOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTaWmI3PzJiaB?= M1f3SWlEPTB;MUC0Mlgh|ryP NIfq[HA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyNFE{Oid-MkW1NlAyOzJ:L3G+
ES-2 MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T2dVczKGh? NWDmU4tjUUN3ME2xOE43KM7:TR?= M4D5PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUKwNVMzLz5{NUWyNFE{OjxxYU6=
OVCAR-8 Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nLfFczKGh? MVHJR|UxRTl4LkCg{txO MlHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkCxN|IoRjJ3NUKwNVMzRC:jPh?=
3AO MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz5O|IhcA>? MnnjTWM2OD14Mz60JO69VQ>? NWr0bFF5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
A2780 M{CwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7NS5E4OiCq NFnIZYRKSzVyPUG0OU44KM7:TR?= NV63ZWhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
SW626 NVXjc3RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DDN|czKGh? MXXJR|UxRTl5LkCg{txO M2rwPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUKwNVMzLz5{NUWyNFE{OjxxYU6=
OVCAR-3 MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XWWVczKGh? MYPJR|UxRTN{Lk[g{txO NXvBUZFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
A549 NUHnNnlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[3[lZKSzVyPUG1NU42PiEEsTC1N{4xPiEQvF2= MkS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
4T1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTh2Lk[yJOKyKDNyLkC1JO69VQpizszN MnT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
BALB/3T3 M12wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjmd3JKSzVyPUG0MlMxKMLzIE[uOlgh|ryP NUfVXYxjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
B16 NH;idJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n0U2lEPTB;NkSuN|AhyrFiNj64NUDPxE1? NFHlWJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Q3OSd-MkWyO|c1PjF:L3G+
DU 145 MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfvNJJKSzVyPUO1MlA1KMLzIEG3MlU1KM7:TR?= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
FaDu MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH5TWJKSzVyPUS1MlM6KMLzIEGxMlUxKM7:TR?= NUHMdpJSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
HCV-29T MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLudI9HUUN3ME20PE42PyEEsTCyNk41QSEQvF2= NHHJSmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Q3OSd-MkWyO|c1PjF:L3G+
HL-60 M2fFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFzLkGwJOKyKDRwNEeg{txO MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
HT-29 NHrMUVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD6fIFrUUN3ME24PU4yPiEEsTCxPE45PiEQvF2= NYPObJRmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PjFpPkK1Nlc4PDZzPD;hQi=>
H146 MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfnTWM2OD12OT62xtEyOy5zIN88US=> NUXXTYo4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
H187 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3ydlNZUUN3ME2xNk44yrF{Lkeg{txO NYH1c4dORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
H128 MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELGWG9KSzVyPUGwOk41yrF7Lk[g{txO MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H69 NEnUVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFmydWZKSzVyPUe2MlnDuTJ5Lkig{txO NGDBdFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
H209 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjXPY5KSzVyPUK1PE4yyrF7OT64JO69VQ>? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
DMS153 NF7wWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:5PXBoUUN3ME21O{45yrF7LkKg{txO NY\lWWZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
H526 M1XYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH1fG9mUUN3ME23MlLDuTFwNzFOwG0> M{DRVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK0NlgzLz5{NUGyOFI5OjxxYU6=
DMS114 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTRTWM2OD16NT64xtEyOi56IN88US=> NVXIfYRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
DMS53 NUXWXHk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[zN2lEPTB;MUS2MlLDuTN4LkSg{txO NVzh[25JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
HeLa NH\xZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X0d|UuQDBizszN NUK3RpdVcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NU\rVIU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFk{PjBpPkK1NVA6OzZyPD;hQi=>
MCF-7 NIW3UJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTjPIpEPS16MDFOwG0> MoPHbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyOUO2NEc,OjVzMEmzOlA9N2F-
MDA-MB-231 MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjxbIw2NThyIN88US=> NEnrW|NqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NX\V[|lHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFk{PjBpPkK1NVA6OzZyPD;hQi=>
CaOV3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfkZXZNPzJiaB?= NHjrTHdKSzVyPUi2MlEh|ryP NEPCOoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
OVCAR-3 NILhTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWW3NkBp NHizdlRKSzVyPUG3PU42KM7:TR?= MofrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNki4OFkoRjJ3ME[4PFQ6RC:jPh?=
OVCAR-5 M{fafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUO3NkBp MlXoTWM2OD15NT63JO69VQ>? M3HpTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
SKOV-3 M4i2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjLZpQ4OiCq NG\jdlBKSzVyPUWwOEDPxE1? MkG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNki4OFkoRjJ3ME[4PFQ6RC:jPh?=
OVCAR-4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjKZ4RCPzJiaB?= MnHBTWM2OD1{OUCuOkDPxE1? NH7kPG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
OVCAR-8 MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT5O|IhcA>? M1vuRWlEPTB;NkmwMlIh|ryP NVPOZ|g1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlg5PDlpPkK1NFY5QDR7PD;hQi=>
MA148 NE\BfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPwNlQhcA>? MWXJR|UxRTh|LkdihKnDueLCiUGuOEDPxGdxbXy= NYHmWYJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
A549 NYi0OmkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS0dJljOjRiaB?= M3G0ZmlEPTB;N{e2MlDjiIoEsfMAjVEvQSEQvHevcYw> M13nfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MDA-MB-231 NEXqVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUiyOEBp M1v6UGlEPTB;N{S4MlDjiIoEsfMAjVEvOSEQvHevcYw> M4HrfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
NCI-ADR/RES  NIG0dGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\s[W8{OjRiaB?= MnLLTWM2OD1zN{WzMlDjiIoEsfMAjVQvPCEQvHevcYw> M4\sUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MA148 NWLJTolnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TyOVQ5KGh? NVPTe5pjUUN3ME2yPE4y6oDLwsJihKkyNjBizsznM41t Ml3FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
A549 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXyOFghcA>? MlLYTWM2OD1zMUiuNQKBkcLz4pEJNU4zKM7:Zz;tcC=> M2e0VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MDA-MB-231 NF\3W2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP5Z2g1QCCq NWq0cGtGUUN3ME2xPFMvOOLCidMx5qCKOS5{IDFOwIcwdWx? NE\s[VQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
NCI-ADR/RES  MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzxV4g1QCCq MW\JR|UxRTF7Mz6w5qCKyrIkgJmxMlkh|rypL33s MlzqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
MA148 M1XUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\MO|czKGh? NID0NWNKSzVyPUGzMlfjiIoEsfMAjVEvOiEQvHevcYw> NXLsRpNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|ExQTFpPkK0PFMyODlzPD;hQi=>
A549 NEezb2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXIO|IhcA>? NHizSZdKSzVyPU[0MlPjiIoEsfMAjVEvOSEQvHevcYw> NF\4XIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
MDA-MB-231 NWPaeVViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfMO|IhcA>? MW\JR|UxRTl7LkZihKnDueLCiUGuNUDPxGdxbXy= NFzhZYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N|ExQTF:L3G+
NCI-ADR/RES  NVLObJlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfZepRiPzJiaB?= NX:5N5dtUUN3ME2zO{416oDLwsJihKkyNjdizsznM41t MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|MUC5NUc,OjR6M{GwPVE9N2F-
A549 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTm[4w6PzJiaB?= NUHlbpNxTE2VTx?= MnvvTWM2OD1zNUKuOFA6KM7:TR?= NH3Xb|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyNVMzOyd-MkS3NlE{OjN:L3G+
NCI-H157 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\BUVczKGh? NXTOUlg2TE2VTx?= MXLJR|UxRTh7Lkm3O{DPxE1? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{MUOyN{c,OjR5MkGzNlM9N2F-
PC9 NFS3V3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\Jb4o4OiCq MVfHR|UxRTdzLkdCtVkvPSEEtV2= MmfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MUi4NFkoRjJ2NkG4PFA6RC:jPh?=
A549  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC5NG04OiCq NHrvOXpISzVyPUGzOuKyOzFwNjFCuW3DqA>? M3rMXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkG4PFA6Lz5{NE[xPFgxQTxxYU6=
PC9 NIHoe3ZCeG:ydH;zbZMhSXO|YYm= NFvFdJkyODBiwsXN MVe3NkBp NFvOeGhqdmS3Y3XzJIFxd3C2b4Ppdy=> MnroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MUi4NFkoRjJ2NkG4PFA6RC:jPh?=
A549  MkXtRZBweHSxc3nzJGF{e2G7 NIfBTnoyODBiwsXN NV3zb2psPzJiaB?= NEG2OnZqdmS3Y3XzJIFxd3C2b4Ppdy=> M2TsPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkG4PFA6Lz5{NE[xPFgxQTxxYU6=
A549 NWLERY9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKyOEBp NGTqSJlKSzFyPUGuOFc3KG6P MkTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OU[0N|coRjJ2M{m2OFM4RC:jPh?=
H1299 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3yx[FI1KGh? MUTJR|ExRTBwNESzJI5O Mo\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OU[0N|coRjJ2M{m2OFM4RC:jPh?=
HCC15 NFPIZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\LNlQhcA>? MUXJR|ExRTBwM{S2JI5O NVH6eZZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N|k3PDN5PD;hQi=>
H157 NFPYZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXkNlQhcA>? NFjn[XlKSzFyPUCuPFEhdk1? MojLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OU[0N|coRjJ2M{m2OFM4RC:jPh?=
A2780 NFvENIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq3TWM2OD1zND6w5qCKyrIkgJmxMlQh|ryP MnH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MEm2PVMoRjJ2MkC5Olk{RC:jPh?=
A2780cisR NHvxTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTR6LkpihKnDueLCiUOuPUDPxE1? Ml3mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MEm2PVMoRjJ2MkC5Olk{RC:jPh?=
A2780ZD0473R M3nkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7YUZhKSzVyPU[0MlbjiIoEsfMAjVMvOiEQvF2= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJyOU[5N{c,OjR{MEm2PVM9N2F-
SKOV-3 NEnRV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\mU2lEPTB;NEOuOQKBkcLz4pEJN{46KM7:TR?= NHHtSnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKwPVY6Oyd-MkSyNFk3QTN:L3G+
Assay
Methods Test Index PMID
Western blot pChK-2 / Chk-2 ; p-p53(S15) / p-p53(S46) / p-p53(S392) / p53 ; p-p38 / p38 / Cleaved PARP / PARP 30049957
Immunofluorescence γH2AX 24348048
Growth inhibition assay Cell viability 24348048
In vivo

In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.

Animal Research:

[1]

  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Dosages: ≤60 mg/kg (When Carboplatin is dissolved in sodium chloride solution, it will induce physio-chemical and pharmacokinetic changes.)
  • Administration: Administered via i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage 2 years 4°C(in the dark) powder
Smiles C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05181462 Not yet recruiting Drug: Carboplatin|Drug: Gemcitabine|Drug: Nadunolimab Triple Negative Breast Cancer Cantargia AB|Spanish Breast Cancer Research Group January 2022 Phase 1|Phase 2
NCT04907968 Recruiting Drug: XMT-1536 (Upifitamab Rilsodotin)|Drug: Carboplatin Platinum-sensitive Ovarian Cancer (UPGRADE-A) Mersana Therapeutics|IQVIA Biotech June 11 2021 Phase 1|Phase 2
NCT04606914 Recruiting Drug: mirvetuximab soravtansine (MIRV; IMGN853) Ovarian Cancer|Fallopian Tube|Primary Peritoneal Cancer University of Alabama at Birmingham May 27 2021 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Can you advise what solvent to use and the concentration for S1215 for in vitro use?

Answer:
DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

Tags: buy Carboplatin (NSC 241240) | Carboplatin (NSC 241240) supplier | purchase Carboplatin (NSC 241240) | Carboplatin (NSC 241240) cost | Carboplatin (NSC 241240) manufacturer | order Carboplatin (NSC 241240) | Carboplatin (NSC 241240) distributor